As medications such as Ozempic have become more widely used, an increasingly common question is whether marijuana can be used at the same time. Ozempic contains semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that changes blood-sugar regulation, appetite, digestion and gastric emptying. Cannabis can affect several of those same systems, particularly through tetrahydrocannabinol (THC), the cannabinoid primarily responsible for marijuana’s intoxicating effects. That overlap raises reasonable questions about nausea, appetite, blood sugar, dizziness and digestion.
The short answer is that there is currently no established direct drug interaction between marijuana and Ozempic, and marijuana is not listed as a specific contraindication or named interaction in the FDA prescribing information for Ozempic. However, that does not mean the combination has been proven safe. Human clinical trials specifically testing cannabis together with semaglutide are essentially absent. Instead, the potential concerns come from what researchers already know about the separate physiological effects of cannabis and GLP-1 drugs. For some people, occasional cannabis use may create few noticeable problems; for others—particularly those experiencing gastrointestinal side effects, taking additional diabetes medications or using cannabis heavily—the combination deserves more caution.
How Ozempic and Semaglutide Affect the Body
Ozempic is an injectable form of semaglutide approved by the U.S. Food and Drug Administration for adults with type 2 diabetes, including certain cardiovascular and kidney-risk indications. Semaglutide mimics the hormone GLP-1, helping the pancreas release insulin when blood glucose is elevated, reducing inappropriate glucagon secretion and influencing brain pathways involved in hunger and satiety. These effects can substantially reduce food intake. In a randomized University of Leeds study involving adults with obesity, once-weekly semaglutide reduced total daily energy intake by approximately 24 percent while reducing hunger, food cravings and preference for high-fat foods. More recently, a 60-week randomized trial led by researchers at the University of Pennsylvania found that people receiving semaglutide continued to consume significantly less food than placebo-treated participants even after many months of treatment.
Semaglutide also affects the gastrointestinal tract. The FDA states that Ozempic delays gastric emptying and warns that gastrointestinal adverse reactions can sometimes be severe. Nausea, vomiting, diarrhea, abdominal pain and constipation are among its most frequently reported side effects, and the medication is not recommended for people with severe gastroparesis. The gastric-emptying effect can be most noticeable during treatment initiation or dose increases and may diminish with continued treatment in some patients. The American Diabetes Association‘s 2026 Standards of Care accordingly recommend gradual titration, smaller meals and individualized management when gastrointestinal symptoms occur.
The Biggest Potential Overlap Is Digestion and Gastric Emptying
The most biologically plausible concern with marijuana and semaglutide involves the stomach rather than a conventional drug-metabolism interaction. THC interacts with cannabinoid CB1 receptors throughout the gastrointestinal system and can reduce gastrointestinal motility. In a double-blind randomized human experiment, researchers gave healthy volunteers THC or placebo and measured gastric emptying after a solid meal. Gastric emptying was significantly slower following THC, with the effect occurring in every participant studied. Although the trial was small and involved pharmaceutical THC rather than ordinary modern cannabis products, it demonstrates that cannabinoids can directly influence gastric motility in humans.
That creates a potential additive effect because semaglutide can also slow stomach emptying. Researchers have not established that people combining marijuana with Ozempic will necessarily develop gastroparesis, nor is there evidence showing that the two substances invariably produce dangerous gastric slowing. Nevertheless, someone who already experiences persistent fullness, reflux, abdominal discomfort, constipation, nausea or vomiting from Ozempic may find cannabis worsens gastrointestinal symptoms. Current GLP-1 clinical recommendations emphasize hydration and prompt evaluation when vomiting or diarrhea becomes prolonged because volume depletion can contribute to kidney injury. The FDA similarly warns that semaglutide-associated vomiting and diarrhea have occasionally resulted in acute kidney injury associated with dehydration.
Marijuana Can Reduce Nausea—But Heavy Use Can Also Cause Severe Vomiting
Cannabis has a complicated relationship with nausea. THC and cannabinoid-based medicines have long been investigated as antiemetics, and FDA-approved synthetic cannabinoid medications such as dronabinol and nabilone have specific medical applications. Some marijuana users therefore report that cannabis relieves nausea experienced after beginning a GLP-1 medication. But using marijuana as a self-treatment for Ozempic-related nausea is not as straightforward as it might seem because frequent cannabis exposure can paradoxically cause the opposite problem.
Cannabinoid hyperemesis syndrome (CHS) causes recurrent episodes of intense nausea, vomiting and abdominal pain in some people who use cannabis chronically or heavily. An American Gastroenterological Association clinical update recognizes CHS as a clinically important disorder associated with prolonged cannabis exposure, while a 2025 review involving researchers from Ohio State University, the University of California Riverside and other academic centers describes sustained cannabis cessation as central to resolving the syndrome. CDC surveillance published in August 2026 also highlights the growing clinical recognition of CHS in U.S. emergency departments. Because Ozempic itself can cause nausea and vomiting, continued cannabis use can make it particularly difficult to determine which substance is responsible when severe gastrointestinal symptoms develop.
What About the Munchies and Ozempic Weight Loss?
THC’s effect on appetite may also work in the opposite direction from semaglutide. GLP-1 medications generally reduce hunger, increase satiety and decrease food reward. THC is well known for producing increased appetite in at least some users, and controlled human research supports the phenomenon. In one randomized placebo-controlled experiment, oral THC increased participants’ reported desire for high-calorie foods and resulted in significantly greater consumption of a chocolate milkshake when participants were allowed to drink freely. Another controlled laboratory study investigating different cannabis administration routes documented changes in appetite-related hormones, including ghrelin, insulin and GLP-1.
This does not mean marijuana automatically cancels the weight-loss effect of semaglutide. Semaglutide produces powerful and sustained effects on appetite regulation, and cannabis responses vary considerably according to THC dose, tolerance, product composition and frequency of use. Someone using marijuana occasionally may notice little effect on their eating patterns, whereas another person may experience strong cravings and substantially increase snacking or calorie intake. For people using semaglutide primarily to improve weight management, paying attention to whether cannabis repeatedly triggers high-calorie eating may therefore be more useful than assuming the two drugs chemically neutralize one another. Semaglutide’s appetite effects remain measurable for months in controlled trials, including the recent University of Pennsylvania study.
Cannabis, Ozempic and Blood Sugar
Another concern is hypoglycemia, particularly for people taking Ozempic for diabetes. Semaglutide stimulates insulin secretion in a glucose-dependent manner, which means Ozempic by itself generally carries a relatively low risk of severe hypoglycemia. The situation changes when semaglutide is combined with insulin or medications that directly stimulate insulin release, such as sulfonylureas. The FDA specifically warns that these combinations can increase the risk of hypoglycemia and that doses of insulin or insulin secretagogues sometimes need to be reduced. The ADA makes the same point in its treatment guidance.
There is not convincing evidence that marijuana itself routinely causes clinically meaningful hypoglycemia. An older human study of chronic cannabis users found no hypoglycemia after marijuana exposure even during fasting or glucose-tolerance testing, although the experiment was extremely small by modern standards. A more practical concern is that THC intoxication can impair attention, memory and decision-making. Controlled and systematic research consistently finds temporary cognitive impairment following THC exposure, meaning that someone who also uses insulin or another hypoglycemia-producing medication could theoretically have more difficulty noticing, interpreting or responding appropriately to early low-blood-sugar symptoms. This is especially relevant for people whose diabetes treatment includes several medications rather than Ozempic alone.
Heart Rate, Blood Pressure, Dizziness and Dehydration
Cannabis also produces cardiovascular effects that may become relevant when someone is experiencing Ozempic side effects. THC can acutely increase heart rate and alter blood pressure. A systematic review of randomized trials found cannabinoid exposure associated with higher rates of hypotension and orthostatic hypotension, while the CDC notes that marijuana can cause an immediate increase in heart rate and blood pressure. These effects are highly variable and depend on THC dose, previous cannabis exposure and the individual user’s cardiovascular health.
The interaction here is again more physiological than pharmacological. A person who is eating substantially less because of semaglutide—or losing fluids because of nausea, vomiting or diarrhea—may already be prone to dehydration or lightheadedness. Adding a substance capable of producing tachycardia or postural blood-pressure changes could make dizziness more noticeable. The concern becomes greater in people with cardiovascular disease, kidney disease or medications that lower blood pressure. The FDA advises monitoring kidney function when Ozempic-related gastrointestinal reactions could cause volume depletion, and current GLP-1 clinical guidance emphasizes maintaining adequate fluid intake when gastrointestinal side effects occur.
THC, CBD and Edibles May Not Carry the Same Risks
It is useful to distinguish THC-containing marijuana from CBD products. Cannabinoids—particularly CBD—can inhibit several cytochrome P450 liver enzymes and therefore interact with many prescription drugs. A controlled human pharmacokinetic study found that a high-CBD cannabis extract inhibited several CYP enzymes, whereas the THC-dominant preparation tested did not show the same pattern. However, semaglutide is different from many conventional medications: research on its metabolism shows that it is primarily broken down through proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty-acid side chain, rather than depending primarily on CYP450 metabolism. That makes a major CBD-driven CYP interaction with semaglutide itself biologically less likely, although CBD may still interact with other medications the same person takes.
Edibles present another unanswered question. The FDA warns that Ozempic’s effect on gastric emptying can influence absorption of orally administered medications, while the CDC notes that edible cannabis can already take substantially longer to produce noticeable effects than inhaled cannabis. No good clinical study has determined exactly how semaglutide changes THC absorption from marijuana edibles. It is therefore reasonable to consider the onset of edible cannabis potentially less predictable in someone experiencing pronounced semaglutide-related gastric slowing. A delayed onset should not automatically be interpreted as evidence that an edible has “not worked,” because taking additional THC before the first dose has fully taken effect can increase the likelihood of excessive intoxication.
So, Can You Smoke Marijuana While Taking Ozempic?
For most patients, there is currently no evidence of a specific toxic chemical reaction between semaglutide and cannabis, and the FDA does not identify marijuana as a prohibited drug combination with Ozempic. The more important issue is overlapping effects. Cannabis—especially THC-rich products—can affect gastric emptying, nausea, appetite, heart rate, blood pressure and cognition, while semaglutide affects appetite, gastrointestinal motility and glucose regulation. Those overlapping actions mean the experience can vary substantially from one person to another.
Extra caution is appropriate if someone is newly starting Ozempic, increasing the dose, experiencing persistent nausea or vomiting, has known gastroparesis, uses cannabis daily or heavily, has previously experienced cannabinoid hyperemesis syndrome, takes insulin or sulfonylureas, or has significant kidney or cardiovascular disease. Persistent vomiting, inability to keep fluids down, severe abdominal pain, fainting, signs of dehydration or symptoms suggesting severe hypoglycemia warrant medical evaluation rather than simply assuming they are ordinary Ozempic or marijuana side effects. The safest approach is to tell the clinician prescribing semaglutide about cannabis use—including THC, CBD, edibles and medical marijuana—so that the entire medication and health picture can be considered.
The Bottom Line
Current evidence does not establish marijuana and Ozempic as a forbidden combination, but it also does not demonstrate that simultaneous use is risk-free. There have not been adequate clinical trials specifically examining cannabis users taking semaglutide. Instead, the evidence points toward several areas where the two can plausibly overlap, with gastric emptying and gastrointestinal symptoms presenting the clearest concern. THC can delay gastric emptying, semaglutide can do the same, and both cannabis and Ozempic can become associated with significant nausea and vomiting under certain circumstances.
For people who tolerate Ozempic well and use cannabis infrequently, a clinically significant interaction may never occur. People experiencing digestive problems or using high-THC cannabis frequently deserve considerably more caution. Ultimately, the question is less about a single proven “marijuana–Ozempic interaction” and more about how cannabis alters the same physiological systems semaglutide is already changing. Until controlled studies specifically examine the combination, individual symptoms, other medications, cannabis dose and frequency of use remain central to assessing risk.
